Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026
Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

Fineline Cube Jul 8, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories

Fineline Cube Jan 26, 2024

Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to...

Company Drug

Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia

Fineline Cube Jan 26, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the...

Company Drug

Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis

Fineline Cube Jan 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

MSD Partners with Variational AI to Harness Generative AI for Drug Discovery

Fineline Cube Jan 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...

Company Drug

Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin

Fineline Cube Jan 26, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Policy / Regulatory

China’s NHC Designates 100 Areas as National Demonstration Zones for Integrated Medical and Elderly Care

Fineline Cube Jan 26, 2024

The National Health Commission (NHC) has announced the selection of 100 counties (cities, districts), including...

Company Drug

Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors

Fineline Cube Jan 26, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the...

Company Drug

Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study

Fineline Cube Jan 26, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...

Company Drug

Pfizer’s Nurtec Approved by China’s NMPA for Acute Treatment of Migraines

Fineline Cube Jan 26, 2024

Pfizer Inc. (NYSE: PFE), a leading pharmaceutical company in the U.S., has announced that it...

Company Drug

Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard

Fineline Cube Jan 26, 2024

Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...

Company

BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application

Fineline Cube Jan 25, 2024

The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s...

Company

Wantai Biological Forecasts Sharp Drop in 2023 Net Profits Amid HPV Vaccine Sales Slump

Fineline Cube Jan 25, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, has issued...

Company Drug

Eli Lilly’s Subsidiary Akouos Reports Positive Preliminary Results for Gene Therapy in Hearing Loss

Fineline Cube Jan 25, 2024

Eli Lilly (NYSE: LLY) has announced preliminary results from a Phase I/II study conducted by...

Company Deals R&D

Shanghai Pharmaceuticals and HKSTPC Launch 01LABS@Hong Kong Incubator

Fineline Cube Jan 25, 2024

01LABS@Hong Kong, a Shanghai-Hong Kong innovation incubator, has officially commenced operations. The incubator was jointly...

Company Drug

Biosion’s SIRPα-Targeting Monoclonal Antibody BSI-082 Clears US FDA Clinical Trial Hurdle

Fineline Cube Jan 25, 2024

Biosion, a global clinical-stage biotechnology company dedicated to developing antibody-based therapies for immune and oncologic...

Company Drug

IASO Biotherapeutics Secures NMPA Approval for Fucaso in Refractory Myasthenia Gravis

Fineline Cube Jan 25, 2024

China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...

Company Drug

MSD’s Keytruda Combines with PharmAbcine’s PMC-309 in Phase Ia/b Solid Tumor Trial

Fineline Cube Jan 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its blockbuster anti-PD-1 drug Keytruda...

Policy / Regulatory

NMPA Proposes Streamlined Market Approval Process for Domestically Produced Overseas Drugs

Fineline Cube Jan 25, 2024

The National Medical Products Administration (NMPA) has released a draft proposal titled “Optimizing the Market...

Company Deals

GSK In-Licenses Elegen’s Cell-Free DNA Tech to Advance Next-Gen Gene Therapies and Vaccines

Fineline Cube Jan 25, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has this week in-licensed US partner Elegen’s...

Policy / Regulatory

NMPA Expands Generic Drug Catalog with 74th and 75th Batches for Quality Consistency Evaluation

Fineline Cube Jan 25, 2024

The National Medical Products Administration (NMPA) has released the 74th and 75th batches of reference...

Posts pagination

1 … 434 435 436 … 691

Recent updates

  • MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001
  • Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure
  • Biocytogen and Whitehawk Forge Global BsADC Partnership to Accelerate Next-Generation Cancer Therapies
  • Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China
  • China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Company Drug

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

Others

Biocytogen and Whitehawk Forge Global BsADC Partnership to Accelerate Next-Generation Cancer Therapies

Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.